Hidradenitis Suppurativa (HS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Hidradenitis Suppurativa (HS) Market Outlook

Thelansis’s “Hidradenitis Suppurativa (HS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hidradenitis Suppurativa treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hidradenitis Suppurativa (HS) Overview

Hidradenitis suppurativa (HS), also known as acne inversus, is a chronic inflammatory skin disorder characterized by lesions such as deep-seated nodules, abscesses, draining tracts, and fibrotic scars. These lesions typically develop in areas where skin rubs together or where there are many sweat glands, with common sites including the axillary, groin, perianal, perineal, and inframammary regions. Depending on the stage of the disease, individuals may experience painful, tender papules, cysts, or nodules, along with areas of scar tissue. The condition may also involve the discharge of foul-smelling pus from the skin and the formation of sinus tracts under the skin. While there is no cure for HS, various treatment options are available based on the severity of the condition. For mild to moderate cases, treatment may involve the use of antibiotic creams, lotions, or washes, oral antibiotics, local steroid injections, minor surgical procedures, laser therapy, and hormone-regulating medications. In cases of more severe disease, these treatments may still be beneficial, along with injectable biologic agents, more extensive surgical procedures, oral immunosuppressive drugs, and other systemic medications.

• The prevalence of hidradenitis suppurativa is estimated to range from 0.5% to 4%, affecting approximately 11 in 100,000 individuals in the United States. Females are more commonly affected than males.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: